As recently developed in ALL preclinical studies, the dual PI3K-mTOR inhibitor BEZ235 controls apoptosis markers [135] such as expression of pro-apoptotic BIM and anti-apoptotic MCL1, thereby restores GC sensitivity [136]. Here, MTOR is linked to acute lymphoblastic leukemia.